Refocusing the debate: evidence-based clinical cancer research versus marketplace reality.
The continued development and licensing of modestly beneficial high-priced treatments, and the potential for widening disparities in cancer care, warrant a renewed focus on how we measure and define benefits and cost.
Markman
Maurie
M